Chimeric Therapeutics Limited
CHMMF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | -$0 | $0 |
| % Growth | 28.4% | 258.1% | -164% | – |
| Cost of Goods Sold | $0 | $0 | -$0 | $0 |
| Gross Profit | $0 | $0 | -$0 | $0 |
| % Margin | 88.1% | 100% | 100% | 200% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | -$0 | $0 |
| Other Operating Expenses | $0 | $0 | -$0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | -$0 | -$0 | $0 |
| % Margin | -105.1% | -47.9% | 477.6% | 48.4% |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | $0 |
| Pre-Tax Income | -$0 | -$0 | -$0 | -$0 |
| Tax Expense | $0 | $0 | -$0 | $0 |
| Net Income | -$0 | -$0 | -$0 | $0 |
| % Margin | -106.2% | -51.5% | 426.3% | 44.6% |
| EPS | -0.005 | -0.003 | -0.022 | 0.004 |
| % Growth | -60.7% | 87.3% | -600% | – |
| EPS Diluted | -0.005 | -0.003 | -0.022 | 0.004 |
| Weighted Avg Shares Out | 2 | 1 | 1 | 1 |
| Weighted Avg Shares Out Dil | 2 | 1 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | -$0 | $0 |
| % Margin | -46% | -39.1% | 383.4% | 40.9% |